Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 601


Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activities.

Luo W, Tweedie D, Beedie SL, Vargesson N, Figg WD, Greig NH, Scerba MT.

Bioorg Med Chem. 2018 Feb 10. pii: S0968-0896(17)32310-6. doi: 10.1016/j.bmc.2018.01.032. [Epub ahead of print]


Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Feb 7. doi: 10.1097/CAD.0000000000000596. [Epub ahead of print]


The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.

Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA.

Fluids Barriers CNS. 2018 Jan 15;15(1):2. doi: 10.1186/s12987-017-0088-8.


Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.


Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, Thompson IM, Ambrosone CB.

Carcinogenesis. 2018 Feb 9;39(2):125-133. doi: 10.1093/carcin/bgx144.


Expanding the use of abiraterone in prostate cancer: Is earlier always better?

Schmidt KT, Madan RA, Figg WD.

Cancer Biol Ther. 2018 Feb 1;19(2):97-100. doi: 10.1080/15384047.2017.1394555. Epub 2017 Dec 8. No abstract available.


Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.


Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.

Wang J, Yeung BZ, Cui M, Peer CJ, Lu Z, Figg WD, Guillaume Wientjes M, Woo S, Au JL.

J Control Release. 2017 Dec 28;268:147-158. doi: 10.1016/j.jconrel.2017.10.020. Epub 2017 Oct 18.


CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos.

Mahony C, McMenemy S, Rafipay AJ, Beedie SL, Fraga LR, Gütschow M, Figg WD, Erskine L, Vargesson N.

J Anat. 2018 Apr;232(4):568-574. doi: 10.1111/joa.12712. Epub 2017 Oct 10.


Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier.

Peer CJ, Chau CH, Figg WD.

Clin Cancer Res. 2017 Dec 15;23(24):7437-7439. doi: 10.1158/1078-0432.CCR-17-2741. Epub 2017 Oct 10.


Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Sissung TM, McKeeby JW, Patel J, Lertora JJ, Kumar P, Flegel WA, Adams SD, Eckes EJ, Mickey F, Plona TM, Mellot SD, Baugher RN, Wu X, Soppet DR, Barcus ME, Datta V, Pike KM, DiPatrizio G, Figg WD, Goldspiel BR.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S67-S77. doi: 10.1002/jcph.993.


Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system.

Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):521-536. doi: 10.1007/s10928-017-9543-z. Epub 2017 Sep 14.


A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC.

Cancer Chemother Pharmacol. 2017 Sep;80(3):645-652. doi: 10.1007/s00280-017-3382-x. Epub 2017 Jul 22.


Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.

Hauke RJ Jr, Sissung TM, Figg WD.

Cancer Biol Ther. 2017 Aug 3;18(8):545-546. doi: 10.1080/15384047.2017.1345398. Epub 2017 Jul 5.


Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.


Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.


Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.

Rodgers L, Peer CJ, Figg WD.

Cancer Biol Ther. 2017 Jul 3;18(7):470-472. doi: 10.1080/15384047.2017.1323600. Epub 2017 May 5.


Cellular identity crisis: Antiandrogen resistance by lineage plasticity.

Tuerff D, Sissung T, Figg WD.

Cancer Biol Ther. 2017 Nov 2;18(11):841-842. doi: 10.1080/15384047.2017.1323599. Epub 2017 May 5.


Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.


Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.

Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF.

Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2.


Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.


A new predictive tool for postoperative radiotherapy in prostate cancer.

Lee DK, Figg WD.

Cancer Biol Ther. 2017 May 4;18(5):277-278. doi: 10.1080/15384047.2017.1310347. Epub 2017 Apr 18.


Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, van Velkinburgh J, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jager W, Price DK, Chau CH, Figg WD.

Mol Cancer Res. 2017 Aug;15(8):1096-1105. doi: 10.1158/1541-7786.MCR-16-0477. Epub 2017 Apr 7.


A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.

Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, Yarchoan R.

Oncologist. 2017 May;22(5):505-e49. doi: 10.1634/theoncologist.2016-0486. Epub 2017 Mar 24.


Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.

League-Pascual JC, Lester-McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE.

J Neurooncol. 2017 May;132(3):401-407. doi: 10.1007/s11060-017-2388-x. Epub 2017 Mar 13.


Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer.

Feinman HE, Price DK, Figg WD.

Cancer Biol Ther. 2017 Apr 3;18(4):203-204. doi: 10.1080/15384047.2017.1295192. Epub 2017 Feb 25.


Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.

Backman JD, O'Connell JR, Tanner K, Peer CJ, Figg WD, Spencer SD, Mitchell BD, Shuldiner AR, Yerges-Armstrong LM, Horenstein RB, Lewis JP.

Pharmacogenet Genomics. 2017 Apr;27(4):159-163. doi: 10.1097/FPC.0000000000000272.


Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter.

Dao K, Chtioui H, Lu Y, Peer CJ, Figg WD, Pruijm M, Buclin T, Kissling S.

Am J Kidney Dis. 2017 Apr;69(4):553-554. doi: 10.1053/j.ajkd.2016.10.026. Epub 2017 Jan 4. No abstract available.


Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.

Dao K, Lu Y, Peer CJ, Figg WD, Stadelmann R, Burnier M, Buclin T, Kissling S.

Cancer Chemother Pharmacol. 2017 Jan;79(1):215-218. doi: 10.1007/s00280-016-3219-z. Epub 2016 Dec 17.


Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold.

Chan ST, Nani RR, Schauer EA, Martin GE, Williamson RT, Saurí J, Buevich AV, Schafer WA, Joyce LA, Goey AK, Figg WD, Ransom TT, Henrich CJ, McKee TC, Moser A, MacDonald SA, Khan S, McMahon JB, Schnermann MJ, Gustafson KR.

J Org Chem. 2016 Nov 18;81(22):10631-10640. Epub 2016 Nov 10.


Vertebrate embryos as tools for anti-angiogenic drug screening and function.

Beedie SL, Diamond AJ, Fraga LR, Figg WD, Vargesson N.

Reprod Toxicol. 2017 Jun;70:49-59. doi: 10.1016/j.reprotox.2016.11.013. Epub 2016 Nov 22.


Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.

Sissung TM, Deeken J, Leibrand CR, Price DK, Ehrlich S, Steinberg SM, Liewehr DJ, Dahut W, Figg WD.

Pharmacogenomics. 2016 Dec;17(18):1979-1986. Epub 2016 Nov 24.


Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.

Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, Goncalves PH, Khetani V, Figg WD, Steinberg SM, Zeldis JB, Yarchoan R.

J Clin Oncol. 2016 Dec;34(34):4125-4131. Epub 2016 Oct 31.


Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF.

J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.


Androgen receptor variation affects prostate cancer progression and drug resistance.

McCrea E, Sissung TM, Price DK, Chau CH, Figg WD.

Pharmacol Res. 2016 Dec;114:152-162. doi: 10.1016/j.phrs.2016.10.001. Epub 2016 Oct 7. Review.


Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Korde N, Landgren O.

Leuk Lymphoma. 2017 Mar;58(3):639-645. doi: 10.1080/10428194.2016.1214953. Epub 2016 Aug 9.


Synthesis and Antiangiogenic Properties of Tetrafluorophthalimido and Tetrafluorobenzamido Barbituric Acids.

Ambrożak A, Steinebach C, Gardner ER, Beedie SL, Schnakenburg G, Figg WD, Gütschow M.

ChemMedChem. 2016 Dec 6;11(23):2621-2629. doi: 10.1002/cmdc.201600496. Epub 2016 Nov 2.


A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma.

Ferraz Nogueira Filho MA, Peer CJ, Nguyen J, McCalla A, Helman L, Figg WD.

J Pharm Biomed Anal. 2017 Jan 5;132:223-226. doi: 10.1016/j.jpba.2016.10.003. Epub 2016 Oct 5.


Pharmacogenomics and histone deacetylase inhibitors.

Goey AK, Sissung TM, Peer CJ, Figg WD.

Pharmacogenomics. 2016 Nov;17(16):1807-1815. Epub 2016 Oct 21. Review.


Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC.

Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.


ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.

O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE.

Breast Cancer Res Treat. 2016 Nov;160(1):51-59. Epub 2016 Sep 12.


Erratum to: Association of a CYP17 Polymorphism With Overall Survival in Caucasian Patients With Androgen-independent Prostate Cancer.

Sissung TM, Venzon DJ, Figg WD.

Urology. 2016 Sep;95:225. doi: 10.1016/j.urology.2016.05.047. Epub 2016 Jul 14. No abstract available.


Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.

Wei BR, Michael HT, Halsey CH, Peer CJ, Adhikari A, Dwyer JE, Hoover SB, El Meskini R, Kozlov S, Weaver Ohler Z, Figg WD, Merlino G, Simpson RM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):643-655. doi: 10.1111/pcmr.12512. Epub 2016 Sep 22.


Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.

Beedie SL, Mahony C, Walker HM, Chau CH, Figg WD, Vargesson N.

Sci Rep. 2016 Jul 22;6:30038. doi: 10.1038/srep30038.


A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.

Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, Madan RA, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL.

Clin Genitourin Cancer. 2017 Feb;15(1):77-85. doi: 10.1016/j.clgc.2016.05.010. Epub 2016 May 27.


Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.

Schmidt KT, Chau CH, Price DK, Figg WD.

J Clin Pharmacol. 2016 Dec;56(12):1484-1499. doi: 10.1002/jcph.765. Epub 2016 Jun 17. Review.


Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF.

Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27.


Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD.

Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10.


YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?

Kyritsi F, Price DK, Figg WD.

Cancer Biol Ther. 2016 Jun 2;17(6):592-4. doi: 10.1080/15384047.2016.1178883. Epub 2016 May 5.


Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.

Goey AK, Chau CH, Sissung TM, Cook KM, Venzon DJ, Castro A, Ransom TR, Henrich CJ, McKee TC, McMahon JB, Grkovic T, Cadelis MM, Copp BR, Gustafson KR, Figg WD.

J Nat Prod. 2016 May 27;79(5):1267-75. doi: 10.1021/acs.jnatprod.5b00846. Epub 2016 May 3.


Supplemental Content

Support Center